Linked Life Data

11740805

Source:http://linkedlifedata.com/resource/pubmed/id/11740805

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Suppl 17
pubmed:dateCreated
2001-12-13
pubmed:abstractText
The development of the targeted signal transduction inhibitor imatinib mesylate (formerly STI571, [Gleevec]; Novartis Pharmaceuticals Corp, East Hanover, NJ) has prompted new ways of thinking about the treatment of chronic myeloid leukemia, other sensitive solid tumors such as gastrointestinal stromal tumors, and malignancies in general. The stresses associated with the extraordinary pace of testing and approval of imatinib mesylate provide lessons to government regulatory agencies, pharmaceutical companies, university researchers, professional societies, and the media in terms of their approach to cancer care, drug development, and dissemination of information. Such medical breakthroughs can generate an enormous, and occasionally overwhelming, volume of new information to be assimilated; misinformation and exaggeration should be avoided. Furthermore, in today's Internet age of information, a large fraction of a patient's medical knowledge and/or opinions may have been obtained and forged online, with input from other patients, and patients are clearly more informed about their illnesses and their options than in the past. The availability of imatinib mesylate has already profoundly changed the nature and sequence of treatment recommendations for patients with chronic myeloid leukemia, but a great deal still remains to be learned and new clinical trials must be designed to address numerous questions about the optimal use of this powerful new medication.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0093-7754
pubmed:author
pubmed:copyrightInfo
Copyright 2001 by W.B. Saunders Company.
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
34-9
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Signal transduction inhibition: changing paradigms in cancer care.
pubmed:affiliation
Barbara Ann Karmanos Cancer Center Institute, Wayne State University School of Medicine, Detroit, MI, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't